By Colin Kellaher
Elevation Oncology has won Food and Drug Administration fast-track designation for EO-3021, its lead drug candidate, in certain patients with gastrointestinal cancers.
Elevation on Monday said the designation covers EO-3021 in adults with advanced or metastatic gastric and gastroesophageal junction cancer expressing the marker protein Claudin 18.2 that has progressed on or after prior therapy.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.
Elevation, a Boston oncology company, is studying EO-3021 in a Phase 1 trial in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 23, 2024 07:57 ET (11:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.